Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.

被引：0
|
作者：
Kurbacher, Christian M.
Eichler, Christian A.
Quade, Annegret Barbara
Kunstmann, Gerhard
Herz, Susanne
Kurbacher, Jutta Anna
Warm, Mathias R.
机构：
[1] Gynecol Ctr Bonn Friedenspl, Bonn, Germany
[2] Krankenhaus Koln Holweide, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
597
引用
收藏
页数：2
相关论文
共 50 条
  • [31] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
    Endo, Yumi
    Dong, Yu
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Yamashita, Hiroko
    Sato, Shinya
    Takahashi, Satoru
    Fujii, Yoshitaka
    Toyama, Tatsuya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
  • [32] HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
    Tse, Chantal
    Gauchez, Anne-Sophie
    Jacot, William
    Lamy, Pierre-Jean
    CANCER TREATMENT REVIEWS, 2012, 38 (02) : 133 - 142
  • [33] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
    Zidan, J.
    Mzalbat, R.
    Svalb, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S142 - S142
  • [34] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
    Kong, Sun-Young
    Nam, Byung-Ho
    Lee, Keun Seok
    Kwon, Youngmee
    Lee, Eun Sook
    Seong, Moon-Woo
    Lee, Do Hoon
    Ro, Jungsil
    CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515
  • [35] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
    Zidan, J.
    Mzalbat, R.
    Shnaider, J.
    Sharabi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [37] Prospective Evaluation of Serum HER2 and HER2 Expression on Circulating Tumor Cells in Patients with Metastatic Breast Cancer within the DETECT Study
    Mueller, V
    Riethdorf, S.
    Rack, B.
    Janni, W.
    Fasching, P.
    Pantel, K.
    Gebauser, G.
    Solomayer, E.
    Aktas, B.
    Kasemier-Bauer, S.
    Fehm, T.
    CANCER RESEARCH, 2009, 69 (24) : 662S - 662S
  • [38] Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
    Peng, Zhi
    Liu, Yi
    Li, Yanyan
    Zhang, Xiaotian
    Zhou, Jun
    Lu, Ming
    Li, Qingqing
    Shen, Lin
    BIOMARKERS IN MEDICINE, 2014, 8 (05) : 663 - 670
  • [39] The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
    Foged, Niels T.
    Brugmann, Anja
    Jorgensen, Jan T.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (03) : 233 - 242
  • [40] Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
    Vivien H. C. Bramwell
    Gordon S. Doig
    Alan B. Tuck
    Sylvia M. Wilson
    Katia S. Tonkin
    Anna Tomiak
    Francisco Perera
    Theodore A. Vandenberg
    Ann F. Chambers
    Breast Cancer Research and Treatment, 2009, 114
12345